News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine

Articles by Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine

Emerging Therapies for HCC Management

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Metastatic HCC Unmet Needs

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

I/O Second-Line Treatment

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

REACH and REACH2 Trial Overview

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Second-Line Therapy: Monoclonal Antibody

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Second-Line Sequencing After IMbrave150 Regimen

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

R/R HCC: Second-Line Options

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Frontline I/O: Clinical Trial Overviews

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Frontline Therapy: Promising I/O Combinations

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Phase 3 IMbrave150 Trial

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Frontline Decision Factors for Metastatic Disease

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Treatment Algorithm: Asia and Europe

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Transitioning From Locoregional to Systemic Therapy

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Diagnosis and Prognosis

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

The Evolving Role of Medical Oncologists and Hepatologists

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Global Screening Programs for At-Risk Populations

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Etiologic Risk Factors and Global Prevalence

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Latest Updated Articles

Frontline I/O: Clinical Trial Overviews
Published: June 29th 2020 | Updated:
R/R HCC: Second-Line Options
Published: June 29th 2020 | Updated:
REACH and REACH2 Trial Overview
Published: June 29th 2020 | Updated:
I/O Second-Line Treatment
Published: June 29th 2020 | Updated:
HCC Treatment Algorithm: Asia and Europe
Published: June 29th 2020 | Updated:
Frontline Therapy: Promising I/O Combinations
Published: June 29th 2020 | Updated:

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care